XML 35 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Earnings Per Common Share Attributable to Common Shareholders
3 Months Ended
Apr. 01, 2018
Earnings Per Share [Abstract]  
Earnings Per Common Share Attributable to Common Shareholders
Earnings Per Common Share Attributable to Common Shareholders
The following table provides the detailed calculation of EPS:
 
 
Three Months Ended
(IN MILLIONS)
 
April 1,
2018

 
April 2,
2017

EPS Numerator––Basic
 
 
 
 
Income from continuing operations
 
$
3,571

 
$
3,130

Less: Net income attributable to noncontrolling interests
 
9

 
9

Income from continuing operations attributable to Pfizer Inc.
 
3,562

 
3,121

Less: Preferred stock dividends––net of tax
 

 

Income from continuing operations attributable to Pfizer Inc. common shareholders
 
3,562

 
3,121

Discontinued operations––net of tax
 
(1
)
 

Net income attributable to Pfizer Inc. common shareholders
 
$
3,560

 
$
3,121

EPS Numerator––Diluted
 
 

 
 

Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions
 
$
3,562

 
$
3,121

Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions
 
(1
)
 

Net income attributable to Pfizer Inc. common shareholders and assumed conversions
 
$
3,561

 
$
3,121

EPS Denominator
 
 

 
 

Weighted-average number of common shares outstanding––Basic
 
5,957

 
6,006

Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements
 
100

 
86

Weighted-average number of common shares outstanding––Diluted
 
6,057

 
6,092

Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans(a)
 
2

 
48

(a) 
These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.